Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 46 entries
Sorted by: Best Match Show Resources per page
Psychological and sexual disorders in long-term breast cancer survivors.

Cancer management and research

Pumo V, Milone G, Iacono M, Giuliano SR, Di Mari A, Lopiano C, Bordonaro S, Tralongo P.
PMID: 22427732
Cancer Manag Res. 2012;4:61-5. doi: 10.2147/CMAR.S28547. Epub 2012 Feb 24.

BACKGROUND: The progressive increase in the number of patients surviving long term after a diagnosis of malignant disease has led to a focus on the early and late complications of the disease and its treatment. The aim of this...

Cite
Pumo V, Milone G, Iacono M, et al. Psychological and sexual disorders in long-term breast cancer survivors. Cancer Manag Res. 2012;4:61-5doi: 10.2147/CMAR.S28547.
Pumo, V., Milone, G., Iacono, M., Giuliano, S. R., Di Mari, A., Lopiano, C., Bordonaro, S., & Tralongo, P. (2012). Psychological and sexual disorders in long-term breast cancer survivors. Cancer management and research, 461-5. https://doi.org/10.2147/CMAR.S28547
Pumo, Vitalinda, et al. "Psychological and sexual disorders in long-term breast cancer survivors." Cancer management and research vol. 4 (2012): 61-5. doi: https://doi.org/10.2147/CMAR.S28547
Pumo V, Milone G, Iacono M, Giuliano SR, Di Mari A, Lopiano C, Bordonaro S, Tralongo P. Psychological and sexual disorders in long-term breast cancer survivors. Cancer Manag Res. 2012;4:61-5. doi: 10.2147/CMAR.S28547. Epub 2012 Feb 24. PMID: 22427732; PMCID: PMC3304333.
Copy Download .nbib Format: NLM
An Interview with David B. Nash, MD, MBA: a perspective on population health and the future direction of healthcare.

MD advisor : a journal for New Jersey medical community

Persichilli JM, Puro JS.
PMID: 29286602
MD Advis. 2017;10(4):33-36.

No abstract available.

Cite
Persichilli JM, Puro JS. An Interview with David B. Nash, MD, MBA: a perspective on population health and the future direction of healthcare. MD Advis. 2017;10(4):33-36
Persichilli, J. M., & Puro, J. S. (2017). An Interview with David B. Nash, MD, MBA: a perspective on population health and the future direction of healthcare. MD advisor : a journal for New Jersey medical community, 10(4), 33-36.
Persichilli, Judith M, and Puro, Janet S. "An Interview with David B. Nash, MD, MBA: a perspective on population health and the future direction of healthcare." MD advisor : a journal for New Jersey medical community vol. 10,4 (2017): 33-36.
Persichilli JM, Puro JS. An Interview with David B. Nash, MD, MBA: a perspective on population health and the future direction of healthcare. MD Advis. 2017;10(4):33-36. PMID: 29286602.
Copy Download .nbib Format: NLM
Mapping and Ablation of Idiopathic Ventricular Fibrillation.

Frontiers in cardiovascular medicine

Cheniti G, Vlachos K, Meo M, Puyo S, Thompson N, Denis A, Duchateau J, Takigawa M, Martin C, Frontera A, Kitamura T, Lam A, Bourier F, Klotz N, Derval N, Sacher F, Jais P, Dubois R, Hocini M, Haissaguerre M.
PMID: 30280100
Front Cardiovasc Med. 2018 Sep 18;5:123. doi: 10.3389/fcvm.2018.00123. eCollection 2018.

Idiopathic ventricular fibrillation (IVF) is the main cause of unexplained sudden cardiac death, particularly in young patients under the age of 35. IVF is a diagnosis of exclusion in patients who have survived a VF episode without any identifiable...

Cite
Cheniti G, Vlachos K, Meo M, et al. Mapping and Ablation of Idiopathic Ventricular Fibrillation. Front Cardiovasc Med. 2018;5:123doi: 10.3389/fcvm.2018.00123.
Cheniti, G., Vlachos, K., Meo, M., Puyo, S., Thompson, N., Denis, A., Duchateau, J., Takigawa, M., Martin, C., Frontera, A., Kitamura, T., Lam, A., Bourier, F., Klotz, N., Derval, N., Sacher, F., Jais, P., Dubois, R., Hocini, M., & Haissaguerre, M. (2018). Mapping and Ablation of Idiopathic Ventricular Fibrillation. Frontiers in cardiovascular medicine, 5123. https://doi.org/10.3389/fcvm.2018.00123
Cheniti, Ghassen, et al. "Mapping and Ablation of Idiopathic Ventricular Fibrillation." Frontiers in cardiovascular medicine vol. 5 (2018): 123. doi: https://doi.org/10.3389/fcvm.2018.00123
Cheniti G, Vlachos K, Meo M, Puyo S, Thompson N, Denis A, Duchateau J, Takigawa M, Martin C, Frontera A, Kitamura T, Lam A, Bourier F, Klotz N, Derval N, Sacher F, Jais P, Dubois R, Hocini M, Haissaguerre M. Mapping and Ablation of Idiopathic Ventricular Fibrillation. Front Cardiovasc Med. 2018 Sep 18;5:123. doi: 10.3389/fcvm.2018.00123. eCollection 2018. PMID: 30280100; PMCID: PMC6153961.
Copy Download .nbib Format: NLM
Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players.

International journal of environmental research and public health

Villalon-Gasch L, Penichet-Tomas A, Sebastia-Amat S, Pueo B, Jimenez-Olmedo JM.
PMID: 35010722
Int J Environ Res Public Health. 2022 Jan 01;19(1). doi: 10.3390/ijerph19010462.

The purpose of this study was to verify if a conditioning activity was effective to elicit postactivation performance enhancement (PAPE) and to increase the performance in vertical jump (VJ) in elite female volleyball players. Eleven national Superliga-2 volleyball players...

Cite
Villalon-Gasch L, Penichet-Tomas A, Sebastia-Amat S, et al. Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players. Int J Environ Res Public Health. 2022;19(1)doi: 10.3390/ijerph19010462.
Villalon-Gasch, L., Penichet-Tomas, A., Sebastia-Amat, S., Pueo, B., & Jimenez-Olmedo, J. M. (2022). Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players. International journal of environmental research and public health, 19(1), . https://doi.org/10.3390/ijerph19010462
Villalon-Gasch, Lamberto, et al. "Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players." International journal of environmental research and public health vol. 19,1 (2022). doi: https://doi.org/10.3390/ijerph19010462
Villalon-Gasch L, Penichet-Tomas A, Sebastia-Amat S, Pueo B, Jimenez-Olmedo JM. Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players. Int J Environ Res Public Health. 2022 Jan 01;19(1). doi: 10.3390/ijerph19010462. PMID: 35010722.
Copy Download .nbib Format: NLM
Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players.

International journal of environmental research and public health

Villalon-Gasch L, Penichet-Tomas A, Sebastia-Amat S, Pueo B, Jimenez-Olmedo JM.
PMID: 35010722
Int J Environ Res Public Health. 2022 Jan 01;19(1). doi: 10.3390/ijerph19010462.

The purpose of this study was to verify if a conditioning activity was effective to elicit postactivation performance enhancement (PAPE) and to increase the performance in vertical jump (VJ) in elite female volleyball players. Eleven national Superliga-2 volleyball players...

Cite
Villalon-Gasch L, Penichet-Tomas A, Sebastia-Amat S, et al. Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players. Int J Environ Res Public Health. 2022;19(1)doi: 10.3390/ijerph19010462.
Villalon-Gasch, L., Penichet-Tomas, A., Sebastia-Amat, S., Pueo, B., & Jimenez-Olmedo, J. M. (2022). Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players. International journal of environmental research and public health, 19(1), . https://doi.org/10.3390/ijerph19010462
Villalon-Gasch, Lamberto, et al. "Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players." International journal of environmental research and public health vol. 19,1 (2022). doi: https://doi.org/10.3390/ijerph19010462
Villalon-Gasch L, Penichet-Tomas A, Sebastia-Amat S, Pueo B, Jimenez-Olmedo JM. Postactivation Performance Enhancement (PAPE) Increases Vertical Jump in Elite Female Volleyball Players. Int J Environ Res Public Health. 2022 Jan 01;19(1). doi: 10.3390/ijerph19010462. PMID: 35010722; PMCID: PMC8744649.
Copy Download .nbib Format: NLM
Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study.

Nordic journal of psychiatry

Poletti M, Pelizza L, Azzali S, Garlassi S, Scazza I, Paterlini F, Chiri LR, Pupo S, Raballo A.
PMID: 34185607
Nord J Psychiatry. 2021 Jun 29;1-9. doi: 10.1080/08039488.2021.1942547. Epub 2021 Jun 29.

PURPOSE: Aberrant salience (AS) is conceptualized as a potential predisposing factor for psychotic states of mind. Despite several studies in the general population, research on AS in the early phases of psychosis is still relatively scarce. The aim of...

Cite
Poletti M, Pelizza L, Azzali S, et al. Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study. Nord J Psychiatry. 2021;1-9doi: 10.1080/08039488.2021.1942547.
Poletti, M., Pelizza, L., Azzali, S., Garlassi, S., Scazza, I., Paterlini, F., Chiri, L. R., Pupo, S., & Raballo, A. (2021). Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study. Nordic journal of psychiatry, 1-9. https://doi.org/10.1080/08039488.2021.1942547
Poletti, Michele, et al. "Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study." Nordic journal of psychiatry vol. (2021): 1-9. doi: https://doi.org/10.1080/08039488.2021.1942547
Poletti M, Pelizza L, Azzali S, Garlassi S, Scazza I, Paterlini F, Chiri LR, Pupo S, Raballo A. Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study. Nord J Psychiatry. 2021 Jun 29;1-9. doi: 10.1080/08039488.2021.1942547. Epub 2021 Jun 29. PMID: 34185607.
Copy Download .nbib Format: NLM
Aberrant salience in first-episode psychosis: Longitudinal stability and treatment-response.

Early intervention in psychiatry

Scazza I, Pelizza L, Azzali S, Garlassi S, Paterlini F, Chiri LR, Poletti M, Pupo S, Raballo A.
PMID: 34786863
Early Interv Psychiatry. 2021 Nov 16; doi: 10.1111/eip.13243. Epub 2021 Nov 16.

AIM: Aberrant salience (AS) is considered a putative predisposing factor for the onset of psychosis. However, despite several studies conducted in the general population, research in early psychosis is still relatively scarce. The main purposes of this study were...

Cite
Scazza I, Pelizza L, Azzali S, et al. Aberrant salience in first-episode psychosis: Longitudinal stability and treatment-response. Early Interv Psychiatry. 2021;doi: 10.1111/eip.13243.
Scazza, I., Pelizza, L., Azzali, S., Garlassi, S., Paterlini, F., Chiri, L. R., Poletti, M., Pupo, S., & Raballo, A. (2021). Aberrant salience in first-episode psychosis: Longitudinal stability and treatment-response. Early intervention in psychiatry, . https://doi.org/10.1111/eip.13243
Scazza, Ilaria, et al. "Aberrant salience in first-episode psychosis: Longitudinal stability and treatment-response." Early intervention in psychiatry vol. (2021). doi: https://doi.org/10.1111/eip.13243
Scazza I, Pelizza L, Azzali S, Garlassi S, Paterlini F, Chiri LR, Poletti M, Pupo S, Raballo A. Aberrant salience in first-episode psychosis: Longitudinal stability and treatment-response. Early Interv Psychiatry. 2021 Nov 16; doi: 10.1111/eip.13243. Epub 2021 Nov 16. PMID: 34786863.
Copy Download .nbib Format: NLM
Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy.

Vaccines

Rivasi G, Bulgaresi M, Mossello E, Buscemi P, Lorini C, Balzi D, Barucci R, Del Lungo I, Gangemi S, Giardini S, Piga C, Barghini E, Boni S, Bulli G, Carrai P, Crociani A, Faraone A, Lo Forte A, Martella L, Pupo S, Fortini G, Marozzi I, Bandini G, Cosma C, Stacchini L, Vaccaro G, Baggiani L, Landini G, Bonaccorsi G, Ungar A, Benvenuti E.
PMID: 34696282
Vaccines (Basel). 2021 Oct 13;9(10). doi: 10.3390/vaccines9101174.

Evidence on the effectiveness of SARS-CoV-2 vaccines in nursing home (NHs) residents is limited. We examined the impact of the BNT162b2 mRNA SARS-CoV-2 vaccine on the course of the epidemic in NHs in the Florence Health District, Italy, before...

Cite
Rivasi G, Bulgaresi M, Mossello E, et al. Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy. Vaccines (Basel). 2021;9(10)doi: 10.3390/vaccines9101174.
Rivasi, G., Bulgaresi, M., Mossello, E., Buscemi, P., Lorini, C., Balzi, D., Barucci, R., Del Lungo, I., Gangemi, S., Giardini, S., Piga, C., Barghini, E., Boni, S., Bulli, G., Carrai, P., Crociani, A., Faraone, A., Lo Forte, A., Martella, L., Pupo, S., Fortini, G., Marozzi, I., Bandini, G., Cosma, C., Stacchini, L., Vaccaro, G., Baggiani, L., Landini, G., Bonaccorsi, G., Ungar, A., & Benvenuti, E. (2021). Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy. Vaccines, 9(10), . https://doi.org/10.3390/vaccines9101174
Rivasi, Giulia, et al. "Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy." Vaccines vol. 9,10 (2021). doi: https://doi.org/10.3390/vaccines9101174
Rivasi G, Bulgaresi M, Mossello E, Buscemi P, Lorini C, Balzi D, Barucci R, Del Lungo I, Gangemi S, Giardini S, Piga C, Barghini E, Boni S, Bulli G, Carrai P, Crociani A, Faraone A, Lo Forte A, Martella L, Pupo S, Fortini G, Marozzi I, Bandini G, Cosma C, Stacchini L, Vaccaro G, Baggiani L, Landini G, Bonaccorsi G, Ungar A, Benvenuti E. Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy. Vaccines (Basel). 2021 Oct 13;9(10). doi: 10.3390/vaccines9101174. PMID: 34696282; PMCID: PMC8537408.
Copy Download .nbib Format: NLM
The COVID-19 Pandemic and Italian Public Mental Health Services: Experience and Future Directions.

Journal of patient experience

Pelizza L, Pupo S.
PMID: 33294591
J Patient Exp. 2020 Oct;7(5):642-644. doi: 10.1177/2374373520956857. Epub 2020 Oct 21.

The COVID-19 pandemic has crosses every health care area (from primary care to specialist ones), leading to a review of all public health policies. The use of smart working allows important technological innovations, but it must be accompanied by...

Cite
Pelizza L, Pupo S. The COVID-19 Pandemic and Italian Public Mental Health Services: Experience and Future Directions. J Patient Exp. 2020;7(5):642-644doi: 10.1177/2374373520956857.
Pelizza, L., & Pupo, S. (2020). The COVID-19 Pandemic and Italian Public Mental Health Services: Experience and Future Directions. Journal of patient experience, 7(5), 642-644. https://doi.org/10.1177/2374373520956857
Pelizza, Lorenzo, and Pupo, Simona. "The COVID-19 Pandemic and Italian Public Mental Health Services: Experience and Future Directions." Journal of patient experience vol. 7,5 (2020): 642-644. doi: https://doi.org/10.1177/2374373520956857
Pelizza L, Pupo S. The COVID-19 Pandemic and Italian Public Mental Health Services: Experience and Future Directions. J Patient Exp. 2020 Oct;7(5):642-644. doi: 10.1177/2374373520956857. Epub 2020 Oct 21. PMID: 33294591; PMCID: PMC7705826.
Copy Download .nbib Format: NLM
Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non-schizophrenia spectrum disorders?.

Early intervention in psychiatry

Pelizza L, Azzali S, Paterlini F, Garlassi S, Scazza I, Chiri LR, Poletti M, Pupo S, Raballo A.
PMID: 33238327
Early Interv Psychiatry. 2021 Dec;15(6):1513-1521. doi: 10.1111/eip.13088. Epub 2020 Nov 25.

AIM: Identifying discrete dimensions that underline negative symptoms in First Episode Psychosis (FEP) could improve the understanding and the treatment of such invalidating symptomatology. The aim of this study is to examine the negative symptom structure in FEP individuals...

Cite
Pelizza L, Azzali S, Paterlini F, et al. Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non-schizophrenia spectrum disorders?. Early Interv Psychiatry. 2020;15(6):1513-1521doi: 10.1111/eip.13088.
Pelizza, L., Azzali, S., Paterlini, F., Garlassi, S., Scazza, I., Chiri, L. R., Poletti, M., Pupo, S., & Raballo, A. (2021). Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non-schizophrenia spectrum disorders?. Early intervention in psychiatry, 15(6), 1513-1521. https://doi.org/10.1111/eip.13088
Pelizza, Lorenzo, et al. "Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non-schizophrenia spectrum disorders?." Early intervention in psychiatry vol. 15,6 (2021): 1513-1521. doi: https://doi.org/10.1111/eip.13088
Pelizza L, Azzali S, Paterlini F, Garlassi S, Scazza I, Chiri LR, Poletti M, Pupo S, Raballo A. Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non-schizophrenia spectrum disorders?. Early Interv Psychiatry. 2021 Dec;15(6):1513-1521. doi: 10.1111/eip.13088. Epub 2020 Nov 25. PMID: 33238327.
Copy Download .nbib Format: NLM
Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects.

Drug and chemical toxicology

de Barros JWF, Villela E Silva P, da Silva GV, da Silva KP, Borges CDS, Mueller A, Valencise L, Pupo AS, Kempinas WG.
PMID: 33934680
Drug Chem Toxicol. 2021 May 03;1-13. doi: 10.1080/01480545.2021.1919139. Epub 2021 May 03.

Statins are 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor drugs that lead to serum-cholesterol-lowering effects. Rosuvastatin, a third-generation statin, has shown better results in reducing cholesterol concentrations when compared to other widely prescribed statins. Recent studies by our group reported that rosuvastatin...

Cite
de Barros JWF, Villela E Silva P, da Silva GV, et al. Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects. Drug Chem Toxicol. 2021;1-13doi: 10.1080/01480545.2021.1919139.
de Barros, J. W. F., Villela E Silva, P., da Silva, G. V., da Silva, K. P., Borges, C. D. S., Mueller, A., Valencise, L., Pupo, A. S., & Kempinas, W. G. (2021). Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects. Drug and chemical toxicology, 1-13. https://doi.org/10.1080/01480545.2021.1919139
de Barros, Jorge Willian Franco, et al. "Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects." Drug and chemical toxicology vol. (2021): 1-13. doi: https://doi.org/10.1080/01480545.2021.1919139
de Barros JWF, Villela E Silva P, da Silva GV, da Silva KP, Borges CDS, Mueller A, Valencise L, Pupo AS, Kempinas WG. Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects. Drug Chem Toxicol. 2021 May 03;1-13. doi: 10.1080/01480545.2021.1919139. Epub 2021 May 03. PMID: 33934680.
Copy Download .nbib Format: NLM
Perspectives on Healthcare from the 2019 EJI Excellence in Medicine Honorees.

MD advisor : a journal for New Jersey medical community

Puro JS.
PMID: 31099994
MD Advis. Spring 2019;12(2):11-15.

No abstract available.

Cite
Puro JS. Perspectives on Healthcare from the 2019 EJI Excellence in Medicine Honorees. MD Advis. 0;12(2):11-15
Puro, J. S. (0). Perspectives on Healthcare from the 2019 EJI Excellence in Medicine Honorees. MD advisor : a journal for New Jersey medical community, 12(2), 11-15.
Puro, Janet S. "Perspectives on Healthcare from the 2019 EJI Excellence in Medicine Honorees." MD advisor : a journal for New Jersey medical community vol. 12,2 (0): 11-15.
Puro JS. Perspectives on Healthcare from the 2019 EJI Excellence in Medicine Honorees. MD Advis. Spring 2019;12(2):11-15. PMID: 31099994.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 46 entries